51
|
Cohen MR. Individual and sex differences in speed of handwriting among high school students. Percept Mot Skills 1997; 84:1428-30. [PMID: 9229470 DOI: 10.2466/pms.1997.84.3c.1428] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A group of 153 high school students participated in a cursive handwriting task which required them to copy sentences as quickly as possible. The 78 girls performed significantly better than the 75 boys and a substantial range of speed for each sex was found. The results have implications for more demanding writing and composition processes. Handwriting speed has the potential to act as a limiting factor under some circumstances.
Collapse
|
52
|
Cohen MR. Tick-borne diseases in the United States. South Med J 1997; 90:663. [PMID: 9191750 DOI: 10.1097/00007611-199706000-00019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
53
|
|
54
|
Abstract
Seizures have many causes, and physicians should try not to be shortsighted when an apparent cause seems to leap out. The key is being receptive to the fact that a less obvious source of seizures may exist. In this case, new-onset seizures believed consistent with illicit drug use proved to have an infectious cause.
Collapse
|
55
|
Proulx S, Wilfinger R, Cohen MR. Medication error prevention: profiling one of pharmacy's foremost advocacy efforts for advice on error prevention. PHARMACY PRACTICE MANAGEMENT QUARTERLY 1997; 17:1-9. [PMID: 10166239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Medication errors have become a growing concern with the increase in the number of critically ill patients, in the complexity of drug therapy and in the use of more potent, dangerous drugs. The Institute for Safe Medication Practices (ISMP), a nonprofit organization founded three years ago, is in the forefront of medication error prevention efforts. Working with practitioners, regulatory agencies, healthcare institutions, professional organizations and the pharmaceutical industry, both nationally and internationally, ISMP provides timely and accurate medication safety information through its educational programs, site-reviews, and ongoing publications. This article reviews the work of ISMP and offers recommendations for managers to begin error prevention strategies.
Collapse
|
56
|
Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, Mahowald ML, Schumacher HR, Taylor T, Budiman-Mak E, Cohen MR, Vasey FB, Luggen ME, Mejias E, Silverman SL, Makkena R, Alepa FP, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. ARTHRITIS AND RHEUMATISM 1996; 39:2004-12. [PMID: 8961905 DOI: 10.1002/art.1780391209] [Citation(s) in RCA: 157] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with nonsteroidal antiinflammatory drug therapy. METHODS Two hundred sixty-four patients with AS were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on morning stiffness, back pain, and physician and patient global assessments. RESULTS While longitudinal analysis revealed a trend favoring SSZ in the middle of treatment, no difference was seen at the end of treatment. Response rates were 38.2% for SSZ and 36.1% for placebo (P = 0.73). The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). AS patients with associated peripheral arthritis showed improvement that favored SSZ (P = 0.02). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. CONCLUSION SSZ at a dosage of 2,000 mg/day does not seem to be more effective than placebo in the treatment of AS patients with chronic, longstanding disease. SSZ is well tolerated and may be more effective than placebo in the treatment of AS patients with peripheral joint involvement. This effect is more pronounced in treatment of the peripheral arthritis in this subgroup of AS patients.
Collapse
|
57
|
Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, Cush JJ, Schumacher HR, Silverman SL, Alepa FP, Luggen ME, Cohen MR, Makkena R, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. ARTHRITIS AND RHEUMATISM 1996; 39:2013-20. [PMID: 8961906 DOI: 10.1002/art.1780391210] [Citation(s) in RCA: 325] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. METHODS Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. RESULTS Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. CONCLUSION SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.
Collapse
|
58
|
Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR, Budiman-Mak E, Balestra DJ, Blackburn WD, Cannon GW, Inman RD, Alepa FP, Mejias E, Cohen MR, Makkena R, Mahowald ML, Higashida J, Silverman SL, Parhami N, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Henderson WG. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. ARTHRITIS AND RHEUMATISM 1996; 39:2021-7. [PMID: 8961907 DOI: 10.1002/art.1780391211] [Citation(s) in RCA: 111] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment of reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy. METHODS One hundred thirty-four patients with ReA who had failed to respond to NSAIDs were recruited from 19 clinics, randomized (double-blind) to receive either SSZ or placebo, and followed up for 36 weeks. The definition of treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. RESULTS Longitudinal analysis revealed improvement in the patients taking SSZ compared with those taking placebo, which appeared at 4 weeks and continued through the trial (P = 0.02). At the end of treatment, response rates were 62.3% for SSZ treatment compared with 47.7% for placebo treatment. The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. CONCLUSION SSZ at a dosage of 2,000 mg/day is well tolerated and effective in patients with chronically active ReA.
Collapse
|
59
|
|
60
|
Cohen MR, Isenberg DA. Ultraviolet irradiation in systemic lupus erythematosus: friend or foe? BRITISH JOURNAL OF RHEUMATOLOGY 1996; 35:1002-7. [PMID: 8883441 DOI: 10.1093/rheumatology/35.10.1002] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The long established notion that UV irradiation is always harmful to patients with systemic lupus erythematosus has been challenged by some recent reports of benefit using a form of phototherapy with UV-A1. In the review we discuss the different types of UV radiation, the links between certain forms of such radiation and clinical manifestations and consider the mechanisms involved.
Collapse
|
61
|
Burack JH, Cohen MR, Hahn JA, Abrams DI. Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY : OFFICIAL PUBLICATION OF THE INTERNATIONAL RETROVIROLOGY ASSOCIATION 1996; 12:386-93. [PMID: 8673548 DOI: 10.1097/00042560-199608010-00009] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
We wished to determine the short-term safety and efficacy of a Chinese medicinal herb preparation in treating symptoms of human immunodeficiency virus (HIV) infection in a 12-week randomized, double-blind, placebo-controlled clinical trial in a University-affiliated acquired immunodeficiency syndrome (AIDS) clinic at a public general hospital. Thirty adults with symptomatic HIV infection, no previous AIDS-defining diagnosis, and CD4+ counts of 0.200-0.499 x 10(9)/L (200-499/mm3) received 28 tablets each day of either a standardized oral preparation of 31 Chinese herbs or a cellulose placebo. Primary outcome measures were changes in life satisfaction, perceived health, and number and severity of symptoms. Other outcomes included adherence, and changes in weight, CD4+ count, depression, anxiety, physical and social function, and mental health. Two placebo- and no herb-treated subjects had mild adverse events (AE). Subjects on both arms reported taking 94% of prescribed tablets. No differences between treatment groups reached the p < 0.05 level. Life satisfaction improved in herb-treated [+0.86, 95% confidence interval (CI): +0.29, +1.43] but not in placebo-treated subjects (+0.20, 95% CI -0.35, + 0.75). Number of symptoms was reduced in subjects receiving herbs (-2.2, 95% CI -4.1, -0.3) but not in those receiving placebo (-0.3, 95% CI -3.2, +2.7). There were trends toward greater improvements among herb-treated subjects on all symptom subscales except dermatologic. Believing that one was receiving herbs was strongly associated with reporting that the treatment had helped (p < 0.005), but not with changes in life satisfaction or symptoms. There were improvements in life satisfaction and symptoms among subjects receiving the herbal therapy. Whether Chinese herbs are effective in the management of symptomatic HIV infection can be adequately addressed only by larger trials of longer duration.
Collapse
|
62
|
Cohen MR, Anderson RW, Attilio RM, Green L, Muller RJ, Pruemer JM. Preventing medication errors in cancer chemotherapy. Am J Health Syst Pharm 1996; 53:737-46. [PMID: 8697025 DOI: 10.1093/ajhp/53.7.737] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Recommendations for preventing medication errors in cancer chemotherapy are made. Before a health care provider is granted privileges to prescribe, dispense, or administer antineoplastic agents, he or she should undergo a tailored educational program and possibly testing or certification. Appropriate reference materials should be developed. Each institution should develop a dose-verification process with as many independent checks as possible. A detailed checklist covering prescribing, transcribing, dispensing, and administration should be used. Oral orders are not acceptable. All doses should be calculated independently by the physician, the pharmacist, and the nurse. Dosage limits should be established and a review process set up for doses that exceed the limits. These limits should be entered into pharmacy computer systems, listed on preprinted order forms, stated on the product packaging, placed in strategic locations in the institution, and communicated to employees. The prescribing vocabulary must be standardized. Acronyms, abbreviations, and brand names must be avoided and steps taken to avoid other sources of confusion in the written orders, such as trailing zeros. Preprinted antineoplastic drug order forms containing checklists can help avoid errors. Manufacturers should be encouraged to avoid or eliminate ambiguities in drug names and dosing information. Patients must be educated about all aspects of their cancer chemotherapy, as patients represent a last line of defense against errors. An interdisciplinary team at each practice site should review every medication error reported. Pharmacists should be involved at all sites where antineoplastic agents are dispensed. Although it may not be possible to eliminate all medication errors in cancer chemotherapy, the risk can be minimized through specific steps. Because of their training and experience, pharmacists should take the lead in this effort.
Collapse
|
63
|
|
64
|
Davis NM, Cohen MR. Sterile cockpit. AMERICAN PHARMACY 1995; NS35:11. [PMID: 8546068 DOI: 10.1016/s0160-3450(15)30014-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
65
|
|
66
|
Davis NM, Cohen MR. Computer-generated prescription orders. AMERICAN PHARMACY 1995; NS35:10. [PMID: 7484808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
67
|
Cohen MR, Davis NM. Repackaging bulk chemicals. AMERICAN PHARMACY 1995; NS35:11; 39. [PMID: 7677049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
68
|
Davis NM, Cohen MR. Distractions as a cause of error. AMERICAN PHARMACY 1995; NS35:11. [PMID: 7661092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
69
|
Cohen MR, Davis NM. Focusing on the causes of dispensing errors. AMERICAN PHARMACY 1995; NS35:16-17. [PMID: 7611132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
70
|
Cohen MR. Drug product characteristics that foster drug-use-system errors. Am J Health Syst Pharm 1995; 52:395-9. [PMID: 7757867 DOI: 10.1093/ajhp/52.4.395] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
|
71
|
Davis NM, Cohen MR. Changing how pharmacists think about errors. AMERICAN PHARMACY 1995; NS35:11, 46. [PMID: 7900645 DOI: 10.1016/s0160-3450(15)30203-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
72
|
Cohen MR, Cohen EP. Enthesopathy and atypical gouty arthritis following renal transplantation: a case control study. REVUE DU RHUMATISME (ENGLISH ED.) 1995; 62:86-90. [PMID: 7600077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
AIMS To define associations and causative factors in a musculotendinous pain syndrome occurring after kidney transplantation. METHODS A case-control study was performed. Cases were identified clinically; transplant controls were matched for age, sex, date and type of transplant, and dialysis controls were matched for age, sex, and race. RESULTS All cases had enthesitis and five of seven later developed gouty arthritis. None of the controls had findings. The plasma uric acid was significantly greater in cases compared to both control groups. CONCLUSIONS A painful musculotendinous syndrome may occur after kidney transplantation. The development of gouty arthritis in five of the seven kidney transplant patients suffering from this syndrome and significant hyperuricemia compared with controls suggested an unusual pattern of gout arthropathy.
Collapse
|
73
|
Cohen MR, Davis NM. Problems with using pharmacy computer systems--Part 2. AMERICAN PHARMACY 1994; NS34:18, 74. [PMID: 7856504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
74
|
|
75
|
Tucker LL, Cohen MR, Davis NM. Orientation teaching tool to prevent medication error. Hosp Pharm 1994; 29:984, 986-8, 991. [PMID: 10138580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Patients can be harmed and even killed when a medication error occurs. The following questions are based on actual errors which have been reported through the Medication Error Reporting Program (MERP). This teaching tool is intended as a take home test to make newly hired pharmacists aware of common medication errors. An informed practitioner is another layer of safety in decreasing the possibility of a medication error occurring.
Collapse
|
76
|
Cohen MR. Needleless emergency drug system needs better differentiation from regular prefilled syringes; what an improvement! Hosp Pharm 1994; 29:1018-9. [PMID: 10138577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
|
77
|
Cohen MR, Davis NM. Pharmacy computer systems and patient safety--Part 1. AMERICAN PHARMACY 1994; NS34:20-1. [PMID: 7847241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
78
|
Davis NM, Cohen MR. Avoiding medication mix-ups. AMERICAN PHARMACY 1994; NS34:17,72. [PMID: 7992786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
79
|
Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol 1994; 21:1665-9. [PMID: 7799346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
OBJECTIVE We sought to compare the prevalence of systemic disease in subacute cutaneous lupus erythematosus (SCLE) with systemic lupus erythematosus (SLE). METHODS Clinical and laboratory features of 14 patients with SCLE were compared with 22 age and sex matched controls with SLE. RESULTS Manifestations other than arthritis and skin disease were present in 11/14 (79%) SCLE cases compared with 19/22 (82%) SLE cases. Severe systemic disease occurred in one-half of patients with SCLE (5/7 men, 1/7 women), and most had the papulosquamous pattern. CONCLUSION Systemic manifestations may be as varied in SCLE as in SLE, and severe disease is not unusual. In particular, men with papulosquamous SCLE may be at higher risk for severe extracutaneous disease.
Collapse
|
80
|
|
81
|
|
82
|
|
83
|
Cohen MR, Davis NM, Tucker L. Practitioner review of proposed pharmaceutical trademarks. AMERICAN JOURNAL OF HOSPITAL PHARMACY 1994; 51:1580, 1582. [PMID: 8092165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
84
|
Cohen MR. Reporting medication errors. AMERICAN PHARMACY 1994; NS34:5-6. [PMID: 8059687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
85
|
|
86
|
Cohen MR, Davis NM. Preprinted order forms: 7 tips for troubleshooting. Nursing 1994; 24:49. [PMID: 8152676 DOI: 10.1097/00152193-199404000-00019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
87
|
|
88
|
Cohen MR, Senders J, Davis NM. Failure mode and effects analysis: a novel approach to avoiding dangerous medication errors and accidents. Hosp Pharm 1994; 29:319-30. [PMID: 10133461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
It is time that hospitals realize that human error is inevitable and must be anticipated. A technique developed in the aerospace industry and known as "failure mode and effects analysis" involves identifying mistakes that will happen before they happen, and determining whether the consequences of those mistakes would be tolerable or intolerable. This article shows how this practice can be adapted to a hospital environment by using a continuous quality improvement approach. Examples show how actual fatal errors can be prevented.
Collapse
|
89
|
|
90
|
Cohen MR, Davis NM. Minimizing look-alike generic mix-ups. AMERICAN PHARMACY 1994; NS34:22-3. [PMID: 8192095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
91
|
|
92
|
Cohen MR, Davis NM. Confusing name; tips for storing drugs. AMERICAN PHARMACY 1994; NS34:20-1. [PMID: 8166041 DOI: 10.1016/s0160-3450(15)30526-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
93
|
Davis NM, Cohen MR. A sample of dispensing errors reported. AMERICAN PHARMACY 1993; NS33:22. [PMID: 8249826 DOI: 10.1016/s0160-3450(15)30621-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
94
|
Davis NM, Cohen MR. More look-alike and sound-alike errors. AMERICAN PHARMACY 1993; NS33:32. [PMID: 8237781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
95
|
Cohen MR. Drug alert: packaging leads to fatal errors. Nursing 1993; 23:17. [PMID: 8414238 DOI: 10.1097/00152193-199310000-00006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
96
|
Cohen MR. Pharmacy labeling practices; comments on pharmacy labeling methods. Hosp Pharm 1993; 28:1038-40, 1043. [PMID: 10129139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
|
97
|
|
98
|
Cohen MR, Davis NM. Pharmacists must receive all incident reports involving medications. AMERICAN JOURNAL OF HOSPITAL PHARMACY 1993; 50:1575-6. [PMID: 8368212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
99
|
Cohen MR, Davis NM. Mix-ups with Norvasc and Navane. AMERICAN PHARMACY 1993; NS33:26. [PMID: 8213467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
100
|
Cohen MR. Don't give P.O. drugs i.v. Nursing 1993; 23:25. [PMID: 8327202 DOI: 10.1097/00152193-199307000-00013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|